Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

By J. Wedzicha, D. Banerji, K. Chapman, Jorgen Vestbo, N. Roche, R. T. Ayers, C. Thach, R. Fogel, F. Patalano, C. Vogelmeier. New England Journal of Medicine, 2016

831 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/996aa15dfc546c0e23ded01be3ccedc7329dfe53

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. J. Wedzicha
2. D. Parums

In Pulmonary and Respiratory Medicine

1. J. Wedzicha
2. Jorgen Vestbo
3. A. Anzueto
4. Bartolome Celli
5. R. Rodríguez-Roisín
6. R. Stockley
7. D. Parums
8. P. Barnes

Citations in the corpus

• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 (2019, methodology): “IMPACT also reported a different https://doi.org/10.1183/13993003.00164-2019 7 result to FLAME [34] for the comparison of double combinations, which can be attributed mainly to the different exacerbation risk of the study populations as already discussed.”
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017, background): “LABA/LAMA improves symptoms and health status in COPD patients,(127) is more effective than long-acting bronchodilator monotherapy for preventing exacerbations,(128) and decreases exacerbations to a greater extent than ICS/LABA combination.(129)”